Comparison of the Response Evaluation Criteria in Solid Tumors with Volumetric Measurement for Evaluation of Response and Overall Survival with Liver Metastases from Colorectal Cancer
10.3348/jksr.2019.80.5.906
- Author:
In Seon LEE
1
;
Seung Joon CHOI
;
Cho Rong SEO
;
Jun Seong KIM
Author Information
1. Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. sjchoi1118@gmail.com
- Publication Type:Original Article
- From:Journal of the Korean Radiological Society
2019;80(5):906-918
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE:The aim of this study was to compare the measurements of diameter and volume of hepatic metastases from CT images with the overall survival and tumor response, in patients with unresectable liver metastases of colorectal cancer treated with a targeted agent.
MATERIALS AND METHODS:We recruited 43 patients with unresectable liver metastases of colorectal cancer, in whom targeted therapy was used as the first-line treatment. Three-dimensional quantification of the volume of hepatic metastases was performed for each patient. An independent survival analysis using the Response Evaluation Criteria in Solid Tumors guidelines was performed and compared to the volumetric measurement. Overall survival was evaluated using the Kaplan-Meier analysis and compared to the Cox proportional hazard ratios (HRs) following univariate and multivariate analyses.
RESULTS:In patients classified as non-progressing and progressing by the volumetric criteria, the median overall survival time was 21 months [95% confidence interval (CI): 491.25–768.75] and 11 months (95% CI: 0–949.42), respectively (p = 0.001). Using a multivariate analysis, we found that volumetric response (HR: 3.467; p = 0.002) was a significant factor affecting the overall survival in patients with liver metastases of colorectal cancer.
CONCLUSION:Volumetric assessment of liver metastases could be an alternative predictor of the overall survival of patients with liver metastases of colorectal cancer treated with a targeted agent.
